Elvira Utigalieva, Andrey Morozov, Ohad Shoshany, Aleksandr Suvorov, Mark Taratkin, Celeste Manfredi, Marco Falcone, Evgeny Bezrukov, Harun Fajkovic, Giorgio I Russo, Dmitry Enikeev
{"title":"对精液质量和男性不育的安慰剂效应进行系统回顾和荟萃分析。","authors":"Elvira Utigalieva, Andrey Morozov, Ohad Shoshany, Aleksandr Suvorov, Mark Taratkin, Celeste Manfredi, Marco Falcone, Evgeny Bezrukov, Harun Fajkovic, Giorgio I Russo, Dmitry Enikeev","doi":"10.23736/S2724-6051.24.05559-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Placebo influence on such objective indicators, as sperm quality and infertility, has not been studied previously, but some studies report that placebo may distort even objective outcomes. The aim of current study is to assess the placebo effect on fertility in patients suffering from sperm abnormalities and/or infertility.</p><p><strong>Evidence acquisition: </strong>We conducted a search of two databases (Scopus and MEDLINE) and identified placebo-controlled clinical trials which focused on sperm abnormalities and/or male infertility treatment. Primary outcomes included changes in semen parameters (volume, total count, sperm concentration in semen, progressive motility, morphology (normal cells)). Secondary outcomes included DNA fragmentation and change in pregnancy rate.</p><p><strong>Evidence synthesis: </strong>Seventy-seven articles published from 1983 to 2022 were included. Statistically significant changes were observed for the following values: total sperm count, mean change 0.16 (95% CI 0.05, 0.26); P=0.004, I<sup>2</sup>=75.1%; and progressive motility, mean change 0.13 (95% CI 0.02, 0.24); P=0.026, I<sup>2</sup>=84.9%. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology or DNA fragmentation index. The publication bias for all the values measured with Egger's test and funnel plots was low.</p><p><strong>Conclusions: </strong>The current meta-analysis indicated a statistically significant increase of total sperm count and progressive motility in the placebo group. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology and DNA fragmentation index. These findings should be considered while planning or analyzing placebo-controlled clinical trials.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"76 4","pages":"423-435"},"PeriodicalIF":4.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A systematic review and meta-analysis of the placebo effect on both semen quality and male infertility.\",\"authors\":\"Elvira Utigalieva, Andrey Morozov, Ohad Shoshany, Aleksandr Suvorov, Mark Taratkin, Celeste Manfredi, Marco Falcone, Evgeny Bezrukov, Harun Fajkovic, Giorgio I Russo, Dmitry Enikeev\",\"doi\":\"10.23736/S2724-6051.24.05559-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Placebo influence on such objective indicators, as sperm quality and infertility, has not been studied previously, but some studies report that placebo may distort even objective outcomes. The aim of current study is to assess the placebo effect on fertility in patients suffering from sperm abnormalities and/or infertility.</p><p><strong>Evidence acquisition: </strong>We conducted a search of two databases (Scopus and MEDLINE) and identified placebo-controlled clinical trials which focused on sperm abnormalities and/or male infertility treatment. Primary outcomes included changes in semen parameters (volume, total count, sperm concentration in semen, progressive motility, morphology (normal cells)). Secondary outcomes included DNA fragmentation and change in pregnancy rate.</p><p><strong>Evidence synthesis: </strong>Seventy-seven articles published from 1983 to 2022 were included. Statistically significant changes were observed for the following values: total sperm count, mean change 0.16 (95% CI 0.05, 0.26); P=0.004, I<sup>2</sup>=75.1%; and progressive motility, mean change 0.13 (95% CI 0.02, 0.24); P=0.026, I<sup>2</sup>=84.9%. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology or DNA fragmentation index. The publication bias for all the values measured with Egger's test and funnel plots was low.</p><p><strong>Conclusions: </strong>The current meta-analysis indicated a statistically significant increase of total sperm count and progressive motility in the placebo group. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology and DNA fragmentation index. These findings should be considered while planning or analyzing placebo-controlled clinical trials.</p>\",\"PeriodicalId\":53228,\"journal\":{\"name\":\"Minerva Urology and Nephrology\",\"volume\":\"76 4\",\"pages\":\"423-435\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva Urology and Nephrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23736/S2724-6051.24.05559-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Urology and Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-6051.24.05559-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
介绍:此前尚未研究过安慰剂对精子质量和不育症等客观指标的影响,但一些研究报告称,安慰剂甚至可能扭曲客观结果。本研究旨在评估安慰剂对精子异常和/或不育症患者生育力的影响:我们对两个数据库(Scopus 和 MEDLINE)进行了检索,并确定了安慰剂对照临床试验,这些试验主要针对精子异常和/或男性不育症的治疗。主要结果包括精液参数的变化(体积、总计数、精液中的精子浓度、进行性活力、形态(正常细胞))。次要结果包括 DNA 片段和怀孕率的变化:纳入了从 1983 年到 2022 年发表的 77 篇文章。观察到以下数值有统计学意义的变化:总精子数,平均变化0.16(95% CI 0.05,0.26);P=0.004,I2=75.1%;进行性活力,平均变化0.13(95% CI 0.02,0.24);P=0.026,I2=84.9%。相比之下,安慰剂对精子浓度、精子体积、精子形态或DNA碎片指数没有影响。用Egger检验和漏斗图测量的所有数值的发表偏倚都很低:目前的荟萃分析表明,安慰剂组的精子总数和精子活力有显著的统计学增长。相比之下,安慰剂对精子浓度、精子体积、精子形态和 DNA 破碎指数没有影响。在计划或分析安慰剂对照临床试验时,应考虑这些研究结果。
A systematic review and meta-analysis of the placebo effect on both semen quality and male infertility.
Introduction: Placebo influence on such objective indicators, as sperm quality and infertility, has not been studied previously, but some studies report that placebo may distort even objective outcomes. The aim of current study is to assess the placebo effect on fertility in patients suffering from sperm abnormalities and/or infertility.
Evidence acquisition: We conducted a search of two databases (Scopus and MEDLINE) and identified placebo-controlled clinical trials which focused on sperm abnormalities and/or male infertility treatment. Primary outcomes included changes in semen parameters (volume, total count, sperm concentration in semen, progressive motility, morphology (normal cells)). Secondary outcomes included DNA fragmentation and change in pregnancy rate.
Evidence synthesis: Seventy-seven articles published from 1983 to 2022 were included. Statistically significant changes were observed for the following values: total sperm count, mean change 0.16 (95% CI 0.05, 0.26); P=0.004, I2=75.1%; and progressive motility, mean change 0.13 (95% CI 0.02, 0.24); P=0.026, I2=84.9%. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology or DNA fragmentation index. The publication bias for all the values measured with Egger's test and funnel plots was low.
Conclusions: The current meta-analysis indicated a statistically significant increase of total sperm count and progressive motility in the placebo group. In contrast, placebo did not affect sperm concentration, sperm volume, sperm morphology and DNA fragmentation index. These findings should be considered while planning or analyzing placebo-controlled clinical trials.